Skip to content
The Policy VaultThe Policy Vault

Rinvoq LQ (upadacitinib) — Highmark

Psoriatic Arthritis

Preferred products

  • adalimumab product
  • Enbrel
  • Cimzia
  • Remicade
  • Remicade biosimilars
  • Simponi
  • Simponi Aria

Initial criteria

  • Rheumatoid Arthritis: age ≥18 years, diagnosis of moderate to severe RA, prescribed by or in consultation with a rheumatologist, AND therapeutic failure or intolerance to a preferred adalimumab product or Enbrel (note: trial of Cimzia, infliximab product, or Simponi [Aria or subcutaneous] also counts)
  • Psoriatic Arthritis: Rinvoq ER tablets for age ≥2 years; Rinvoq LQ for age 2–<18 years; diagnosis of PsA; prescribed by or in consultation with rheumatologist or dermatologist; AND failure/intolerance to preferred adalimumab product or Enbrel (note: trial of Cimzia, infliximab product, or Simponi [Aria or subcutaneous] also counts)